BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ibrance (Palbociclib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ibrance (Palbociclib)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02605486-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT02605486)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Palbociclib in Combination With Bicalutamide for the Trea
 tment of AR(+) Metastatic Breast Cancer (MBC)\nEstimated primary completio
 n: November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pal
 bociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT02605486
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04605562-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04605562)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: Umbrella Biomarker-Gui
 ded Therapy in NPC\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04605562
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02738866-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT02738866)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Palbociclib With Fulvestrant for Metastatic Breast Cancer A
 fter Treatment With Palbociclib and an Aromatase Inhibitor\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT02738866
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03820830-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT03820830)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Palbociclib for HR Positive / HER2-negative Isolated Locore
 gional Recurrence of Breast Cancer\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT038208
 30
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04185883-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT04185883)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1.\nStudy: Sotorasib Activity in 
 Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 1
 01)\nEstimated primary completion: 17 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04185883
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468697-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT05468697)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2.\nStudy: A Study of Belzutifa
 n (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy 
 in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-
 024)\nEstimated primary completion: 22 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05468697
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Open-Label Umbrella Study To Evaluate Safety And Efficacy
  Of Elacestrant In Various Combination In Participants With Metastatic Bre
 ast Cancer\nEstimated primary completion: 27 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04216576-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Ibrance (Palbociclib): Phase na readout est. (NCT04216576)
DESCRIPTION:Ibrance (Palbociclib)\, phase na\, HR+/HER2- Metastatic Breast 
 Cancer.\nStudy: A Study of the Use of Text Message Reminders to Take Palbo
 ciclib\nEstimated primary completion: 27 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04216576
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03573648-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT03573648)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, Breast Cancer.\nStudy: Neoadj
 uvant Endocrine Therapy\, Palbociclib\, Avelumab in Estrogen Receptor Posi
 tive Breast Cancer\nEstimated primary completion: 30 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03573648
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909397-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT05909397)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letroz
 ole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\nEstimated prima
 ry completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05909397
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006172-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT03006172)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: To Evaluate the Safety\, Tolerability\, and Pharmacokinetic
 s of Inavolisib Single Agent in Participants With Solid Tumors and in Comb
 ination With Endocrine and Targeted Therapies in Participants With Breast 
 Cancer\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03006172
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739395-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT06739395)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: Precision Medicine Tri
 al Based on Molecular Matching Therapy for Patients With Standard Treatmen
 t Exhaustion\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06739395
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03297606-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT03297606)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: Canadian Profiling and
  Targeted Agent Utilization Trial (CAPTUR)\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pal
 bociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03297606
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04553133-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04553133)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: PF-07104091 as a Single Agent and in Combination Therapy\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04553133
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207734-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT06207734)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Discontinuation of CDK4/6 Inhibitors in Patients With Metas
 tatic HR Positive\, HER2 Negative Breast Cancer\nEstimated primary complet
 ion: 10 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /palbociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06207734
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06126276-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT06126276)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: Testing the Use of Ner
 atinib or the Combination of Neratinib and Palbociclib Targeted Treatment 
 for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)\nEstimated primary c
 ompletion: 20 February 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06126276
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947811-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT06947811)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2.\nStudy: A Study of Almonerti
 nib Combined With Palbociclib in Patients With Advanced Solid Tumors Harbo
 ring KRAS Mutations\nEstimated primary completion: March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06947811
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06736704-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT06736704)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2.\nStudy: SNV4818 in Participa
 nts With Advanced Solid Tumors\nEstimated primary completion: April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06736704
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05216432-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT05216432)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: First-in-Human Study of Mutant-selective PI3Kα Inhibitor\,
  RLY-2608\, as a Single Agent in Patients With Advanced Solid Tumors and i
 n Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Pat
 ients With Advanced Solid Tumors or Advanced Breast Cancer\nEstimated prim
 ary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05216432
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04920708-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04920708)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Fulvestrant\, Ipatasertib and CDK4/6 Inhibition in Metastat
 ic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression\nEstimated p
 rimary completion: June 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04920708
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04438824-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04438824)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: Palbociclib and INCMGA
 00012 in People With Advanced Liposarcoma\nEstimated primary completion: J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT044
 38824
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188520-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT06188520)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A First-in-human Dose Escalation and Expansion Study to E
 valuate the Safety\, and Tolerability of AZD8421 Alone or in Combination i
 n Participants With Selected Advanced or Metastatic Solid Tumors\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06188520
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04841148-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04841148)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Avelumab or Hydroxychloroquine With or Without Palbociclib 
 to Eliminate Dormant Breast Cancer\nEstimated primary completion: July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04841148
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05432518-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT05432518)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1.\nStudy: Pilot Trial for Treatm
 ent of Recurrent Glioblastoma\nEstimated primary completion: 1 July 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05432518
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05238922-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270727
DTEND;VALUE=DATE:20270728
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT05238922)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1.\nStudy: Study of INCB123667 in
  Subjects With Advanced Solid Tumors\nEstimated primary completion: 27 Jul
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05238
 922
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04360941-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT04360941)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1\, HER2-Positive Breast Cancer.\
 nStudy: PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negati
 ve Breast Cancer\nEstimated primary completion: 31 July 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04360941
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03332797-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT03332797)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Study of GDC-9545 Alone or in Combination With Palbocicli
 b and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally A
 dvanced or Metastatic Estrogen Receptor-Positive Breast Cancer\nEstimated 
 primary completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03332797
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03304080-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT03304080)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Anastrozole\, Palbociclib\, Trastuzumab and Pertuzumab in
  HR-positive\, HER2-positive Metastatic Breast\nEstimated primary completi
 on: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pal
 bociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03304080
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06753747-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT06753747)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2.\nStudy: A Trial of the Combi
 nation of Afatinib and Palbociclib in Previously Treated Advanced Esophage
 al Squamous Cell Carcinoma\nEstimated primary completion: September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06753747
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT02925234)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: The Drug Rediscovery P
 rotocol (DRUP Trial)\nEstimated primary completion: September 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04985266-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04985266)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Trial of Early Detection of Molecular Relapse With Circul
 ating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant 
 Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negati
 ve Breast Cancer\nEstimated primary completion: 1 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04985266
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941142-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT06941142)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Study of Sirolimus (Albumin-Bound) in Combination With Pa
 lbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer\nEst
 imated primary completion: October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06941142
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07123090-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT07123090)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: A Study of Sasanlimab\
 , Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma\nEstimated p
 rimary completion: 1 October 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07123090
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04563507-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04563507)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Combined Immunotherapies in Metastatic ER+ Breast Cancer\nE
 stimated primary completion: 31 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04563507
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299890-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT07299890)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, Breast Cancer.\nStudy: An Exp
 loratory Study of Pertuzumab and Trastuzumab in Combination With Palbocicl
 ib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer
 \nEstimated primary completion: 1 November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07299890
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862663-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT04862663)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastati
 c HR+/HER2- Breast Cancer (CAPItello-292)\nEstimated primary completion: 1
  November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbo
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04862663
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05683418-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT05683418)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Study to Evaluate the Safety and Tolerability of TOS-358 
 in Women With HR+ HER2- Breast Cancer\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT056
 83418
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191977-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT07191977)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: Neoadjuvant Camrelizum
 ab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma\nEst
 imated primary completion: December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07191977
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03132454-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT03132454)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1.\nStudy: Palbociclib and Sorafe
 nib\, Decitabine\, or Dexamethasone in Treating Patients With Recurrent or
  Refractory Leukemia\nEstimated primary completion: 31 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03132454
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04693468-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT04693468)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1.\nStudy: Talazoparib and Palboc
 iclib\, Axitinib\, or Crizotinib for the Treatment of Advanced or Metastat
 ic Solid Tumors\, TalaCom Trial\nEstimated primary completion: 31 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT046934
 68
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT06692491)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: Study of Precision Tre
 atment for Rare Tumours in China Guided by PDO and NGS\nEstimated primary 
 completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06692491
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04567420-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04567420)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, Breast Cancer.\nStudy: DNA-gu
 ided Second Line Adjuvant Therapy for High Residual Risk\, Estrogen Recept
 or Positive\, HER-2 Negative Breast Cancer (DARE)\nEstimated primary compl
 etion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/palbociclib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04567420
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT02465060)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Targeted Therapy Directed by Genetic Testing in Treating Pa
 tients With Advanced Refractory Solid Tumors\, Lymphomas\, or Multiple Mye
 loma (The MATCH Screening Trial)\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02465
 060
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05627232-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT05627232)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1.\nStudy: Tazemetostat and Palbo
 ciclib With CPX-351for R/R AML\nEstimated primary completion: January 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05627232
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of AVZO-021 in Patients With Advanced Solid Tumors\
 nEstimated primary completion: 31 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03454035-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280203
DTEND;VALUE=DATE:20280204
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT03454035)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1.\nStudy: Ulixertinib/Palbocicli
 b in Patients With Advanced Pancreatic and Other Solid Tumors\nEstimated p
 rimary completion: 3 February 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03454035
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04931342)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: A Study Evaluating the
  Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persis
 tent or Recurrent Rare Epithelial Ovarian Tumors\nEstimated primary comple
 tion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/palbociclib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04931342
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065748-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT06065748)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Study to Evaluate Efficacy and Safety of Giredestrant Com
 pared With Fulvestrant (Plus a CDK4/6 Inhibitor)\, in Participants With ER
 -Positive\, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant End
 ocrine Therapy (pionERA Breast Cancer)\nEstimated primary completion: 20 A
 pril 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbocicli
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 065748
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002177-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT07002177)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Phase Ib/II Study to Evaluate Multiple Combination Ther
 apies of FWD1802 in Patients With ER+/HER2- BC\nEstimated primary completi
 on: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbo
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07002177
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02942355-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT02942355)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Trial of Anastrozole and Palbociclib in Metastatic HER2-Neg
 ative Breast Cancer\nEstimated primary completion: 30 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT02942355
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06113809-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT06113809)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1.\nStudy: Palbociclib and Pembro
 lizumab in Sarcoma\nEstimated primary completion: July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06113809
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06062498-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT06062498)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patie
 nts With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer\nEs
 timated primary completion: 1 July 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06062498
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843967-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280819
DTEND;VALUE=DATE:20280820
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT06843967)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2.\nStudy: A Study of Mirdameti
 nib in Combination With Palbociclib in People With Liposarcoma\nEstimated 
 primary completion: 19 August 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06843967
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554367-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280826
DTEND;VALUE=DATE:20280827
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT05554367)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: Palbociclib and Binime
 tinib in RAS-Mutant Cancers\, A ComboMATCH Treatment Trial\nEstimated prim
 ary completion: 26 August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/palbociclib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05554367
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377852-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT06377852)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study\nEstimate
 d primary completion: 31 August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06377852
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07861932-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT07861932)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Phase 1/2a Study of K-1728 in Advanced Solid Tumors\nEs
 timated primary completion: September 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07861932
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02896335-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT02896335)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: Palbociclib and Pembro
 lizumab In Central Nervous System Metastases\nEstimated primary completion
 : 1 September 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 albociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT02896335
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997029-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20281214
DTEND;VALUE=DATE:20281215
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT06997029)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Phase 1 Study of BMS-986500 as Monotherapy or Combination
  Therapy in Advanced Solid Tumors\nEstimated primary completion: 14 Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0699
 7029
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04966481-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT04966481)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3.\nStudy: Palbociclib and Cetuxi
 mab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered\, HPV-un
 related Head and Neck Squamous Cell Carcinoma Who Experienced Disease Prog
 ression on a PD-1/L1 Inhibitor\nEstimated primary completion: 28 February 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0496648
 1
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07787520-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ibrance (Palbociclib): Phase 1 readout est. (NCT07787520)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1.\nStudy: A Study of LAE118 as M
 onotherapy and in Combination With Antitumor Agents in Advanced Solid Tumo
 rs\nEstimated primary completion: March 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07787520
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757634-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT06757634)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Phase 3 Study of Gedatolisib as First-Line Treatment for Pa
 tients With HR-Positive\, HER2-Negative Advanced Breast Cancer (VIKTORIA-2
 )\nEstimated primary completion: 31 March 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06757634
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Tr
 eatment Combinations in Participants With Breast Cancer\nEstimated primary
  completion: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04802759
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748208-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290615
DTEND;VALUE=DATE:20290616
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT07748208)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Study Evaluating the Safety of Inavolisib and Fulvestrant
  With or Without Palbociclib in Participants With Advanced Breast Cancer (
 ABC) and Type 2 Diabetes\nEstimated primary completion: 15 June 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07748208
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061717-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT07061717)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Comparing Endocrine Therapy Combined With High-Dose Palboci
 clib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Do
 se Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Br
 east Cancer\nEstimated primary completion: 1 July 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07061717
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT04606446)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of PF-07248144 in Advanced or Metastatic Solid Tumors
 \nEstimated primary completion: 27 August 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT06380751)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine The
 rapy\, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camiz
 estrant in HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified
 )\, BRCA1\, BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary co
 mpletion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/palbociclib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06380751
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926607-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT07926607)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2.\nStudy: Palbociclib\, All-Tr
 ans Retinoic Acid\, and Venetoclax in Relapsed or Refractory Acute Myeloid
  Leukemia\nEstimated primary completion: 31 December 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07926607
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05226871-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT05226871)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study for Participants Continuing From Pfizer-sponsored Pal
 bociclib (a Study Medicine) Studies\nEstimated primary completion: 31 Dece
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palbocicli
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 226871
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monothera
 py and in Combination With Other Antineoplastic Agents in Participants Wit
 h Advanced Solid Tumors\nEstimated primary completion: July 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564377-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT05564377)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Targeted Therapy Directed by Genetic Testing in Treating Pa
 tients With Locally Advanced or Advanced Solid Tumors\, The ComboMATCH Scr
 eening Trial\nEstimated primary completion: 1 July 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05564377
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683754-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300704
DTEND;VALUE=DATE:20300705
SUMMARY:Ibrance (Palbociclib): Phase 3 readout est. (NCT07683754)
DESCRIPTION:Ibrance (Palbociclib)\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual
  HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retre
 atment With T-DXd\nEstimated primary completion: 4 July 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07683754
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Ibrance (Palbociclib): Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Ibrance (Palbociclib)\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Tr
 eatment Combinations in Patients With Metastatic or Locally Advanced Breas
 t Cancer\nEstimated primary completion: 30 September 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-9034@assetmemo.bio
DTSTAMP:20261121T004007Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Ibrance (Palbociclib): Phase 2 readout est. (NCT05725200)
DESCRIPTION:Ibrance (Palbociclib)\, phase 2.\nStudy: Study to Investigate O
 utcome of Individualized Treatment in Patients With Metastatic Colorectal 
 Cancer\nEstimated primary completion: 31 December 2038. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/palbociclib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/palbociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
